好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

White Matter Segmentation Using DIR vs. FLAIR MRI in Tumor Treating Fields Treatment Planning for Glioblastoma
Neuro-oncology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
6-001

This study aims to use quantitative metrics to compare magnetic resonance imaging (MRI) segmentation utilizing Double Inversion Recovery (DIR) and Fluid-Attenuated Inversion Recovery (FLAIR) sequences for Tumor Treating Fields (TTFields) treatment planning.

TTFields therapy is an established adjuvant treatment for glioblastoma patients in combination with surgery, radiation and temozolomide chemotherapy. Treatment planning requires modeling TTFields delivery inside the brain to determine the dose targeting the tumor, and segmentation of the white matter is the most time-consuming process in the workflow. DIR sequence appears to provide better contrast between white and gray matters than FLAIR.

Semi-automated segmentation of the white matter from 3 glioblastoma patients was performed using DIR and FLAIR sequences according to established methods (PMID: 29023236 and 28544575). Dice coefficient and Interaction over Union (IoU) indices were computed for the segmented white matters, together with the volume of the structures and time required for segmentation.

Median Dice coefficient was 0.704 (range 0.678-0.741) and IoU index was 0.543 (range 0.512-0.589).  The median volume of white matter was 327.9 cc (range 317.8-390.5) when segmented using DIR and 343.9 cc (range 324.3-532.8) when segmented using FLAIR.  The time required to complete the segmentation was about 30-45 minutes less for DIR compared to FLAIR.

The Dice coefficient and IoU indices indicate that segmentation using DIR is less prone to over-contouring compared to FLAIR, probably because DIR provides better contrast between white and gray matters. The volumes are comparable but segmentation using DIR requires less time and fewer manual corrections.

Supported in part by The Rhode Island Life Science Hub and The Musella Foundation.

Authors/Disclosures
Eric T. Wong, MD, FAAN (Rhode Island Hospital)
PRESENTER
Dr. Wong has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Wong has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ZaiLab. Dr. Wong has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Turning Point Therapeutics. Dr. Wong has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imvax. The institution of Dr. Wong has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novocure. The institution of Dr. Wong has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Turning Point Therapeutics. The institution of Dr. Wong has received research support from Novocure. Dr. Wong has received intellectual property interests from a discovery or technology relating to health care. Dr. Wong has received publishing royalties from a publication relating to health care.
Olivia Liang Ms. Liang has nothing to disclose.
Edwin Lok, MS, DABR Mr. Lok has received personal compensation for serving as an employee of US Oncology. Mr. Lok has received intellectual property interests from a discovery or technology relating to health care.
Viva Voong Voong Ms. Voong has nothing to disclose.
Neve Constantine Miss Constantine has nothing to disclose.
Tara Lu (Brown University Health) No disclosure on file
Jerrold Boxerman, MD, PhD Dr. Boxerman has nothing to disclose.